Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that
produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at …

Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in
approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating …

Background BCR-ABL kinase domain mutations are infrequently detected in newly
diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Recent studies indicate …

Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase
chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing …

Imatinib mesylate is a selective Bcr-Abl kinase inhibitor, effective in the treatment of chronic
myelogenous leukemia. Most patients in chronic phase maintain durable responses; …

Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with
chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a …

Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence
of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary …

Abstract Treatment of chronic myeloid leukemia (CML) has been drastically changed by the
emergence of the ABL tyrosine kinase inhibitor (TKI), imatinib mesylate. However, resistance …

Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …